These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37070849)

  • 1. N-of-1 Trials in Cancer Drug Development.
    Gouda MA; Buschhorn L; Schneeweiss A; Wahida A; Subbiah V
    Cancer Discov; 2023 Jun; 13(6):1301-1309. PubMed ID: 37070849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps.
    Printz C
    Cancer; 2020 Jan; 126(2):239-240. PubMed ID: 31917472
    [No Abstract]   [Full Text] [Related]  

  • 3. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 5. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy.
    Zhang Z; Wei X
    Semin Cancer Biol; 2023 May; 90():57-72. PubMed ID: 36796530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimizing anti-body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology.
    Subbiah V
    Curr Probl Cancer; 2021 Oct; 45(5):100799. PubMed ID: 34706831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An appraisal of drug development timelines in the Era of precision oncology.
    Jardim DL; Schwaederle M; Hong DS; Kurzrock R
    Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.
    Johnson A; Zeng J; Bailey AM; Holla V; Litzenburger B; Lara-Guerra H; Mills GB; Mendelsohn J; Shaw KR; Meric-Bernstam F
    Drug Discov Today; 2015 Dec; 20(12):1433-8. PubMed ID: 26148707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ushering in the next generation of precision trials for pediatric cancer.
    DuBois SG; Corson LB; Stegmaier K; Janeway KA
    Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definitions and statistical properties of master protocols for personalized medicine in oncology.
    Renfro LA; Mandrekar SJ
    J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Drug Repurposing Accelerate Precision Oncology?
    Schipper LJ; Zeverijn LJ; Garnett MJ; Voest EE
    Cancer Discov; 2022 Jul; 12(7):1634-1641. PubMed ID: 35642948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-centric trials for therapeutic development in precision oncology.
    Biankin AV; Piantadosi S; Hollingsworth SJ
    Nature; 2015 Oct; 526(7573):361-70. PubMed ID: 26469047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?
    Tao DL; Kartika T; Tran A; Prasad V
    Eur J Cancer; 2020 Nov; 139():20-26. PubMed ID: 32957010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative trial design in precision oncology.
    Tsimberidou AM; Müller P; Ji Y
    Semin Cancer Biol; 2022 Sep; 84():284-292. PubMed ID: 33022355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
    Schmidt KT; Chau CH; Price DK; Figg WD
    J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.